Novalar to acquire OraVerse

June 2011
Proofs;Jun2011, Vol. 94 Issue 3, p42
Trade Publication
The article reports on an agreement signed by Novalar Pharmaceuticals Inc. with the company Septodont to acquire the local anesthesia reversal agent OraVerse.


Related Articles

  • Regulatory Update.  // PharmaWatch: CNS;Sep2010, Vol. 9 Issue 9, p13 

    The article reports that the marketing authorization application (MAA) filed by Sanofi-Aventis Deutschland GmbH and Novalar Pharmaceuticals Inc. for local anesthesia reversal agent OraVerse has been accepted for review by regulatory agencies in Great Britain, Germany, Italy, France, and Spain....

  • Corrections & Clarifications.  // BioWorld Today;8/14/2008, Vol. 19 Issue 158, p2 

    A correction to an article in the August 13, 2008 issue regarding Novalar Pharmaceutical Inc.'s 2009 launch of its OraVerse product is presented.

  • Dental Biotech Firm Departs With a Smile. Quigley, Kelly // San Diego Business Journal;3/28/2011, Vol. 32 Issue 13, p1 

    The article reports that local dental biotech company Novalar Pharmaceuticals Inc. has been preparing for the sale of its OraVerse injection drug in the U.S. It indicates that Novalar has created an agreement with dental pharmaceutical company Septodont to sell its oral injection drug. It states...

  • Novalar Gets $30M D Round To Launch Dental Drug NV-101. Morrison, Trista // BioWorld Today;11/2/2007, Vol. 18 Issue 214, p3 

    The article reports on the $30 million venture capital raised through a Series D financing by Novalar Pharmaceuticals Inc. in November 2007. The proceeds will be used to introduce the dental drug NV-101 by the third quarter of 2008. NV-101 is a phentolamine mesylate vasodilator that is indicated...

  • No More Numbness?  // Research at Penn;2009, Vol. 7, p6 

    The article reports on the anti-numbing agent that shorten the length of post-procedure numbness, developed after the multi-center trial funded by Novalar Pharmaceuticals Inc. with the assistance of Andres Pinto from the University of Pennsylvania, Department of Oral Medicine. In the trial,...

  • IMS Health Report Predicts U.S. Drug Sales to Slow in 2008. Chambers, Heather // San Diego Business Journal;11/12/2007, Vol. 28 Issue 46, p14 

    The article offers news briefs related to the pharmaceutical industry in San Diego County, California in November 2007. Amylin Pharmaceuticals Inc. reported that its experimental once-weekly version of Byetta showed significant improvements in lowering glucose levels. Novalar Pharmaceuticals...

  • Illumina Shuttering Connecticut Plant, Relocating 50 Employees. Weeks, Katie // San Diego Business Journal;4/16/2007, Vol. 28 Issue 16, p8 

    The article reports on developments related to biotechnology industry in San Diego County, California. Illumina Inc. is closing its facility in Wallingford, Connecticut. Novalar Pharmaceuticals Inc. submitted a new drug application to the Food and Drug Administration for its local anesthetic...

  • Biotech CEOs Stick With Best Game Plans to, Win Over Investors. Randolph, Ned // San Diego Business Journal;3/24/2008, Vol. 29 Issue 12, p18 

    The article focuses on the views of several biotechnology company chief executive officers (CEO) in San Diego, California concerning the best approach to win over investors. Donna Janson of Novalar Pharmaceuticals Inc. states that it is important that the message is very clear and...

  • Novalar Sinks Its Teeth in $600M Dental Treatment Market. Chambers, Heather // San Diego Business Journal;3/9/2009, Vol. 30 Issue 10, p10 

    The article reports on the launch of OraVerse injection by Novalar Pharmaceuticals Inc. in Carmel Valley, California in February 27, 2009. the product is made with an anti-hypertensive drug that works to reverse the numbering effects of dental anesthesia on half the time. The company aims to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics